Skip to content

Hong Kong Cohort of Abnormal Sleep in Ageing Population (HK-ASAP): Focusing on Brain Health and Sleep Quality

Hong Kong Cohort of Abnormal Sleep in Ageing Population (HK-ASAP): an Observational Study on Brain Health and Sleep Quality in Community-dwelling Older Adults

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06170073
Acronym
HK-ASAP
Enrollment
238
Registered
2023-12-14
Start date
2023-10-01
Completion date
2025-01-10
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Brain Disease, Cognitive Decline, Sleep Disturbance

Keywords

Ageing, Sleep disturbances, Cognition, Brain health, Longevity

Brief summary

Poor sleep quality can significantly jeopardize the brain health, cognitive functions, daily activities, quality of life, and even be implicated as a key potential contributing factor in the development of accelerated cognitive decline and prodromal dementia. Consequently, research efforts to understand, and therefore potentially model, the effects of sleep quality on cognition and brain health are of great pragmatic values.

Detailed description

Objectives: This study aims to investigate the cognitive changes in older adults with sleep disturbances, examine the neuroimaging contributors to poor sleep quality and cognitive deficits.

Interventions

None listed

Sponsors

The University of Hong Kong
CollaboratorOTHER
Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
55 Years to 95 Years
Healthy volunteers
Yes

Inclusion criteria

* Chinese old adults are the ones who are over 60 years of chronological age. * Sleep disturbance: individual's subjective sleep quality is assessed using the Pittsburgh Sleep Quality Index (PSQI) with a total score \>5.

Exclusion criteria

* History of bipolar disorders or psychosis. * History of major neurological deficits, including stroke, transient ischemic attack or brain tumor. * Unable to participant magnetic resonance imaging (MRI) scanning.

Design outcomes

Primary

MeasureTime frameDescription
Complex attention will be measured by the Attention Network Test (ANT)BaselineThe ANT paradigm, as a computerized test, was used and performed by E-Prime 3.0.
Sleep quality will be measured by the Pittsburgh Sleep Quality Index (PSQI)BaselinePittsburgh Sleep Quality Index (PSQI) is a validated 19-item self-reported questionnaire
Global cognition will be measured by the Montreal Cognitive Assessment Hong Kong version (HK MoCA)BaselineThe Montreal Cognitive Assessment Hong Kong version (HK MoCA) is a validated and widely used screening assessment for detecting cognitive impairment, which measures an array of cognitive functions such as visuospatial, memory, language and attention.

Secondary

MeasureTime frameDescription
Memory and learning will be measured by the Word list learning test (WLLT)BaselineWord list learning test (WLLT), consisting of fifteen semantically non-associated words that is presented consecutively over three free trials of immediate recall, a 20-min delayed recall and followed by yes/no recognition.
Executive functions will be measured by the category verbal fluency test (CVFT)BaselineOn each trial of CVFT, the participants will be asked to overtly generate words in the animal category, fruit category and vegetable category as many as possible within 60 seconds
The levels of Aβ40 and Aβ42 will be measured by saliva analysisBaselinesaliva samples will be collected at a consistent time of day to avoid circadian effects and will be kept on ice during the collection.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026